Zhou Y, Chi J, Huang Y, et al. - In this systematic review and meta‐analysis of randomized controlled trials, researchers tested the safety and effectiveness of endothelin receptor antagonists for people with diabetic kidney disease. Randomized controlled trials contrasting endothelin receptor antagonists with placebo in people with diabetic kidney disease have been identified through PubMed, Embase and the Cochrane Library. Seven studies with a total of 4,730 candidates were involved. In individuals with diabetic kidney disease, atrasentan and avosentan, but not bosentan, are effective for renoprotection among endothelin receptor antagonists. Atrasentan 0.75 mg/day is the most promising compared with other types and doses, with maximal reduction of albuminuria and limited fluid retention. In future clinical practice, vigilant monitoring of congestive heart failure risk is required.